<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Bone and soft tissue sarcomas, tumors of the skin</journal-id><journal-title-group><journal-title xml:lang="en">Bone and soft tissue sarcomas, tumors of the skin</journal-title><trans-title-group xml:lang="ru"><trans-title>Саркомы костей, мягких тканей и опухоли кожи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2219-4614</issn><issn publication-format="electronic">2782-3687</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">613</article-id><article-id pub-id-type="doi">10.17650/2782-3687-2023-15-3-11-16</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОРНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Dynamics of the incidence of non-melanoma malignant neoplasms in the Republic of Uzbekistan for the 2018–2022</article-title><trans-title-group xml:lang="ru"><trans-title>Динамика заболеваемости немеланомными злокачественными новообразованиями кожи в Республике Узбекистан за 2018–2022 гг.</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8128-2553</contrib-id><name-alternatives><name xml:lang="en"><surname>Polatova</surname><given-names>D. Sh.</given-names></name><name xml:lang="ru"><surname>Полатова</surname><given-names>Д. Ш.</given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>103 Makhtumkuli St., Tashkent 100047</p></bio><bio xml:lang="ru"><p>100047 Ташкент, ул. Махтумкули, 103</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-4488-7270</contrib-id><name-alternatives><name xml:lang="en"><surname>Ibragimova</surname><given-names>D. А.</given-names></name><name xml:lang="ru"><surname>Ибрагимова</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>Dilorom Abdulazizovna Ibragimova</p><p>103 Makhtumkuli St., Tashkent 100047</p></bio><bio xml:lang="ru"><p>Дилором Абдулазизовна Ибрагимова</p><p>100047 Ташкент, ул. Махтумкули, 103</p></bio><email>ibragimova.m.h@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0064-3746</contrib-id><name-alternatives><name xml:lang="en"><surname>Madaminov</surname><given-names>А. Yu.</given-names></name><name xml:lang="ru"><surname>Мадаминов</surname><given-names>А. Ю.</given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>103 Makhtumkuli St., Tashkent 100047</p></bio><bio xml:lang="ru"><p>100047 Ташкент, ул. Махтумкули, 103</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Davletov</surname><given-names>R. R.</given-names></name><name xml:lang="ru"><surname>Давлетов</surname><given-names>Р. Р.</given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>383 Farobi St., Tashkent 100179</p></bio><bio xml:lang="ru"><p>100179 Ташкент, ул. Фароби, 383</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Savkin</surname><given-names>А. V.</given-names></name><name xml:lang="ru"><surname>Савкин</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>103 Makhtumkuli St., Tashkent 100047</p></bio><bio xml:lang="ru"><p>100047 Ташкент, ул. Махтумкули, 103</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Karimova</surname><given-names>N. M.</given-names></name><name xml:lang="ru"><surname>Каримова</surname><given-names>Н. М.</given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>103 Makhtumkuli St., Tashkent 100047</p></bio><bio xml:lang="ru"><p>100047 Ташкент, ул. Махтумкули, 103</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nurjabov</surname><given-names>А. I.</given-names></name><name xml:lang="ru"><surname>Нуржабов</surname><given-names>А. И.</given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>103 Makhtumkuli St., Tashkent 100047</p></bio><bio xml:lang="ru"><p>100047 Ташкент, ул. Махтумкули, 103</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Аsamedinov</surname><given-names>N. K.</given-names></name><name xml:lang="ru"><surname>Асамединов</surname><given-names>Н. К.</given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>103 Makhtumkuli St., Tashkent 100047</p></bio><bio xml:lang="ru"><p>100047 Ташкент, ул. Махтумкули, 103</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Xamidullaeva</surname><given-names>O. O.</given-names></name><name xml:lang="ru"><surname>Хамидуллаева</surname><given-names>О. О.</given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>103 Makhtumkuli St., Tashkent 100047</p></bio><bio xml:lang="ru"><p>100047 Ташкент, ул. Махтумкули, 103</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Tashkent State Dental Institute</institution></aff><aff><institution xml:lang="ru">Ташкентский государственный стоматологический институт</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology</institution></aff><aff><institution xml:lang="ru">Республиканский специализированный научно-практический медицинский центр онкологии и радиологии</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-09-15" publication-format="electronic"><day>15</day><month>09</month><year>2023</year></pub-date><volume>15</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>11</fpage><lpage>15</lpage><history><date date-type="received" iso-8601-date="2023-09-14"><day>14</day><month>09</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-09-14"><day>14</day><month>09</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Polatova D.S., Ibragimova D.А., Madaminov А.Y., Davletov R.R., Savkin А.V., Karimova N.M., Nurjabov А.I., Аsamedinov N.K., Xamidullaeva O.O.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Полатова Д.Ш., Ибрагимова Д.А., Мадаминов А.Ю., Давлетов Р.Р., Савкин А.В., Каримова Н.М., Нуржабов А.И., Асамединов Н.К., Хамидуллаева О.О.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Polatova D.S., Ibragimova D.А., Madaminov А.Y., Davletov R.R., Savkin А.V., Karimova N.M., Nurjabov А.I., Аsamedinov N.K., Xamidullaeva O.O.</copyright-holder><copyright-holder xml:lang="ru">Полатова Д.Ш., Ибрагимова Д.А., Мадаминов А.Ю., Давлетов Р.Р., Савкин А.В., Каримова Н.М., Нуржабов А.И., Асамединов Н.К., Хамидуллаева О.О.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://sarbon.abvpress.ru/jour/article/view/613">https://sarbon.abvpress.ru/jour/article/view/613</self-uri><abstract xml:lang="en"><p><bold>Introduction. </bold>Non-melanoma skin cancers (NMNCs) are the most common human malignancies and have been on the rise for many years. These tumors is a large heterogeneous group that most often occurs in people over 65 years of age, which is a minority of the population of Uzbekistan. Which means that the calculation of standardized indicators allows us to reveal the true picture of the incidence, adjusted for the age limit.</p><p><bold>Aim. </bold>To study and analyze the incidence rates of non-melanoma malignant skin tumors at the national level.</p><p><bold>Materials and methods. </bold>We conducted a retrospective search in the cancer registry databases for the period from 2018 to 2022 at Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology using International Statistical Classification of Diseases (ICD) 10th revision codes C44.0–C44.9. The study included all initially identified patients aged 18 years and older with a histopathologically confirmed diagnosis of basal or squamous cell carcinoma. All patients were divided into 5-year age intervals to calculate standardized indicators according to the world standard.</p><p><bold>Results. </bold>In total, 4986 cases of NMNCs were detected in Uzbekistan for the period 2018-2022. The results of the analysis of the study showed that the standardized incidence rates were higher than the intensive rates in all years for 2018–2022. From 2018 to 2020, the standardized incidence rate of NMNCs decreased by 33 %. In 2022, it was 3.8 (which is 15 % lower than in 2018). Standardized incidence rates in patients under the age of 40 increased by 50 % from 2018 to 2022, which may indicate a younger incidence of NMNCs.</p><p><bold>Conclusion. </bold>Studying and understanding current epidemiological trends in NMLCs is critical to achieving early and adequate control of these common skin cancers. Effective strategies for primary prevention and screening of skin cancer need to be developed to reduce morbidity and mortality from NMNCs.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение. </bold>Немеланомные злокачественные новообразования кожи (НМЗНК) являются наиболее распространенными злокачественными опухолями человека. Тенденция к росту их встречаемости сохраняется на протяжении многих лет. Эти опухоли представляют собой большую гетерогенную группу и наиболее часто наблюдаются у лиц старше 65 лет, которые составляют меньшинство населения Узбекистана. Расчет стандартизированных показателей позволяет выявить истинную картину заболеваемости с поправкой на возрастное ограничение.</p><p><bold>Цель исследования </bold>– изучение и анализ показателей заболеваемости НМЗНК на республиканском уровне.</p><p><bold>Материалы и методы. </bold>Проведен ретроспективный поиск данных в канцер-регистре Республиканского специализированного научно-практического медицинского центра онкологии и радиологии за период с 2018 по 2022 г. с использованием кодов C44.0–C44.9 по международной классификации болезней 10-го пересмотра (МКБ-10). В исследование включены все пациенты в возрасте 18 лет и старше с первично выявленной и гистологически подтвержденной базально- или плоскоклеточной карциномой. Больные разделены на 5-летние возрастные интервалы для расчета стандартизованных показателей по мировому стандарту.</p><p><bold>Результаты. </bold>Всего в Узбекистане за период с 2018 по 2022 г. выявлены 4986 случаев НМЗНК. Анализ данных продемонстрировал, что стандартизованные показатели заболеваемости были выше, чем интенсивные показатели во все годы (за 2018–2022 гг.). С 2018 по 2020 г. стандартизованный показатель заболеваемости НМЗНК снизился на 33 %. В 2022 г. он составил 3,8 (что на 15 % ниже, чем в 2018 г.). Стандартизованные показатели заболеваемости у пациентов в возрасте до 40 лет с 2018 по 2022 г. увеличились на 50 %, что может свидетельствовать об омоложении заболеваемости НМЗНК.</p><p><bold>Заключение. </bold>С учетом мировых эпидемиологических тенденций в отношении НМЗНК становится очевидным, что существует острая необходимость в контроле заболеваемости этими распространенными видами злокачественных новообразований кожи. Нужно разработать эффективные стратегии первичной профилактики и скрининга рака кожи, чтобы снизить заболеваемость НМЗНК и смертность от них.</p></trans-abstract><kwd-group xml:lang="en"><kwd>non-melanoma malignant neoplasms of the skin</kwd><kwd>basal cell carcinoma</kwd><kwd>squamous cell carcinoma</kwd><kwd>intensive score</kwd><kwd>standardized score</kwd><kwd>incidence</kwd><kwd>detection of the disease</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>немеланомные злокачественные новообразования кожи</kwd><kwd>базальноклеточная карцинома</kwd><kwd>плоскоклеточная карцинома</kwd><kwd>интенсивный показатель</kwd><kwd>стандартизованный показатель</kwd><kwd>заболеваемость</kwd><kwd>выявляемость заболевания</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Australian Institute of Health and Welfare: Cancer Incidence Data 2019. Available at: https://www.aihw.gov.au/reports/.</mixed-citation><mixed-citation xml:lang="ru">Australian Institute of Health and Welfare: Cancer Incidence Data 2019. Available at: https://www.aihw.gov.au/reports/.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Leiter U., Keim U., Garbe C. Epidemiology of skin cancer: update 2019. Adv Exp Med Biol 2020;1268:123–39. DOI: 10.1007/978-3-030-46227-7_6</mixed-citation><mixed-citation xml:lang="ru">Leiter U., Keim U., Garbe C. Epidemiology of skin cancer: update 2019. Adv Exp Med Biol 2020;1268:123–39. DOI: 10.1007/978-3-030-46227-7_6</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Chahal H.S., Rieger K.E., Sarin K.Y. Incidence ratio of basal cell carcinoma to squamous cell carcinoma equalizes with age. J Am Acad Dermatol 2017;76(2):353–4. DOI: 10.1016/j.jaad.2016.08.019</mixed-citation><mixed-citation xml:lang="ru">Chahal H.S., Rieger K.E., Sarin K.Y. Incidence ratio of basal cell carcinoma to squamous cell carcinoma equalizes with age. J Am Acad Dermatol 2017;76(2):353–4. DOI: 10.1016/j.jaad.2016.08.019</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Yuan T.A., Lu Y., Edwards K. et al. Race-, Age-, and Anatomic Site-Specific gender differences in cutaneous melanoma suggest differential mechanisms of early- and late-onset melanoma. Int J Environ ResPublic Health 2019;16(6):908. DOI: 10.3390/ijerph16060908</mixed-citation><mixed-citation xml:lang="ru">Yuan T.A., Lu Y., Edwards K. et al. Race-, Age-, and Anatomic Site-Specific gender differences in cutaneous melanoma suggest differential mechanisms of early- and late-onset melanoma. Int J Environ ResPublic Health 2019;16(6):908. DOI: 10.3390/ijerph16060908</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Sacchetto L., Zanetti R., Comber H. et al. Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer 2018;92:108–18. DOI: 10.1016/j.ejca.2017.12.024</mixed-citation><mixed-citation xml:lang="ru">Sacchetto L., Zanetti R., Comber H. et al. Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer 2018;92:108–18. DOI: 10.1016/j.ejca.2017.12.024</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Garbe C., Keim U., Gandini S. et al. Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943–2036. Eur J Cancer 2021;152:18–25. DOI: 10.1016/j.ejca.2021.04.029</mixed-citation><mixed-citation xml:lang="ru">Garbe C., Keim U., Gandini S. et al. Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943–2036. Eur J Cancer 2021;152:18–25. DOI: 10.1016/j.ejca.2021.04.029</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Matthews N.H., Li W.Q., Qureshi A.A. et al. Epidemiology of melanoma. In: Cutaneous Melanoma: Etiology and Therapy. Ed. by W.H. Ward, J.M. Farma. Brisbane (AU): Codon Publications; 2017 Dec 21. Chapter 1.</mixed-citation><mixed-citation xml:lang="ru">Matthews N.H., Li W.Q., Qureshi A.A. et al. Epidemiology of melanoma. In: Cutaneous Melanoma: Etiology and Therapy. Ed. by W.H. Ward, J.M. Farma. Brisbane (AU): Codon Publications; 2017 Dec 21. Chapter 1.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Prickett K.A., Ramsey M.L. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 25, 2022. Mohs Micrographic Surgery.</mixed-citation><mixed-citation xml:lang="ru">Prickett K.A., Ramsey M.L. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 25, 2022. Mohs Micrographic Surgery.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. PDQ Screening and Prevention Editorial Board. PDQ Cancer Information Summaries. National Cancer Institute (US); Bethesda (MD): Dec 23, 2022. Skin Cancer Prevention (PDQ®): Health Professional Version.</mixed-citation><mixed-citation xml:lang="ru">PDQ Screening and Prevention Editorial Board. PDQ Cancer Information Summaries. National Cancer Institute (US); Bethesda (MD): Dec 23, 2022. Skin Cancer Prevention (PDQ®): Health Professional Version.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Meredith J.W., High K.P., Freischlag J.A. Preserving elective surgeries in the covid -19 pandemic and the future. JAMA 2020;324(17):1725. DOI: 10.1001/jama.2020.19594</mixed-citation><mixed-citation xml:lang="ru">Meredith J.W., High K.P., Freischlag J.A. Preserving elective surgeries in the covid -19 pandemic and the future. JAMA 2020;324(17):1725. DOI: 10.1001/jama.2020.19594</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Dinmohamed A.G., Visser O., Verhoeven R.H.A. et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol 2020;21(6):750–1. DOI: 10.1016/S1470-2045(20)30265-5</mixed-citation><mixed-citation xml:lang="ru">Dinmohamed A.G., Visser O., Verhoeven R.H.A. et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol 2020;21(6):750–1. DOI: 10.1016/S1470-2045(20)30265-5</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Ricci F., Fania L., Paradisi A. et al. Delayed melanoma diagnosis in the COVID-19 era: Increased breslow thickness in primary melanomas seen after the COVID-19 lockdown. J Eur Acad Dermatol Venereol 2020;34(12):e778–9. DOI: 10.1111/jdv.16874</mixed-citation><mixed-citation xml:lang="ru">Ricci F., Fania L., Paradisi A. et al. Delayed melanoma diagnosis in the COVID-19 era: Increased breslow thickness in primary melanomas seen after the COVID-19 lockdown. J Eur Acad Dermatol Venereol 2020;34(12):e778–9. DOI: 10.1111/jdv.16874</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Nolan G.S., Dunne J.A., Kiely A. al.The effect of the COVID-19 pandemic on skin cancer surgery in the United Kingdom: a national, multicentre, prospective cohort study and survey of Plastic Surgeons. Br J Surg 2020;107(12):e598–600. DOI: 10.1002/bjs.12047.</mixed-citation><mixed-citation xml:lang="ru">Nolan G.S., Dunne J.A., Kiely A. al.The effect of the COVID-19 pandemic on skin cancer surgery in the United Kingdom: a national, multicentre, prospective cohort study and survey of Plastic Surgeons. Br J Surg 2020;107(12):e598–600. DOI: 10.1002/bjs.12047.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Andrew T.W., Alrawi M., Lovat P. Reduction in skin cancer diagnoses in the UK during the COVID-19 pandemic. Clin Exp Dermatol 2020;46(1):145–6. DOI: 10.1111/ced.14411</mixed-citation><mixed-citation xml:lang="ru">Andrew T.W., Alrawi M., Lovat P. Reduction in skin cancer diagnoses in the UK during the COVID-19 pandemic. Clin Exp Dermatol 2020;46(1):145–6. DOI: 10.1111/ced.14411</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Wehner M., Dalma N., Landefeld C. et al. Natural history of lesions suspicious for basal cell carcinoma in older adults in Ikaria, Greece. Br J Dermatol 2018;179(3):767–8. DOI: 10.1111/bjd.16730</mixed-citation><mixed-citation xml:lang="ru">Wehner M., Dalma N., Landefeld C. et al. Natural history of lesions suspicious for basal cell carcinoma in older adults in Ikaria, Greece. Br J Dermatol 2018;179(3):767–8. DOI: 10.1111/bjd.16730</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Lattanzi M., Lee Y., Simpson D. et al. Primary melanoma histologic subtype: impact on survival and response to therapy. Gynecol Oncol 2018;111:180–8.</mixed-citation><mixed-citation xml:lang="ru">Lattanzi M., Lee Y., Simpson D. et al. Primary melanoma histologic subtype: impact on survival and response to therapy. Gynecol Oncol 2018;111:180–8.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Eigentler T.K., Leiter U., Häfner H.-M. et al. Survival of patients with cutaneous squamous cell carcinoma: results of a prospective cohort study. J Investig Dermatol 2017;137(11):2309–15. DOI: 10.1016/j.jid.2017.06.025</mixed-citation><mixed-citation xml:lang="ru">Eigentler T.K., Leiter U., Häfner H.-M. et al. Survival of patients with cutaneous squamous cell carcinoma: results of a prospective cohort study. J Investig Dermatol 2017;137(11):2309–15. DOI: 10.1016/j.jid.2017.06.025</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. British Association of Dermatologists BSfDS. COVID-19 Skin Cancer Surgery Guidance. 2020. Available at: http://www.bad.org.uk/healthcare-professionals/covid-19.</mixed-citation><mixed-citation xml:lang="ru">British Association of Dermatologists BSfDS. COVID-19 Skin Cancer Surgery Guidance. 2020. Available at: http://www.bad.org.uk/healthcare-professionals/covid-19.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Miranda B.H., Hughes W.R.M., Pinto-Lopes R. et al. COVID-19 surgery safety (StACS) study: elective plastic surgery, trauma &amp; burns. J Plast Reconstr Aesthet Surg 2021;74(1):211–22. DOI: 10.1016/j.bjps.2020.08.039</mixed-citation><mixed-citation xml:lang="ru">Miranda B.H., Hughes W.R.M., Pinto-Lopes R. et al. COVID-19 surgery safety (StACS) study: elective plastic surgery, trauma &amp; burns. J Plast Reconstr Aesthet Surg 2021;74(1):211–22. DOI: 10.1016/j.bjps.2020.08.039</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Rich H., Jones B., Malin I. et al. Plastic surgical management of skin cancer patients during the COVID-19 pandemic. J Plast Reconstr Aesthet Surg 2021;74(3):644–710. DOI: 10.1016/j.bjps.2020.08.143</mixed-citation><mixed-citation xml:lang="ru">Rich H., Jones B., Malin I. et al. Plastic surgical management of skin cancer patients during the COVID-19 pandemic. J Plast Reconstr Aesthet Surg 2021;74(3):644–710. DOI: 10.1016/j.bjps.2020.08.143</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Rich H., O’Neill T. Major fall in urgent skin cancer referrals during the COVID-19 outbreak. J Plast Reconstr Aesthet Surg 2021;74(3):670–1. DOI: 10.1016/j.bjps.2020.10.087</mixed-citation><mixed-citation xml:lang="ru">Rich H., O’Neill T. Major fall in urgent skin cancer referrals during the COVID-19 outbreak. J Plast Reconstr Aesthet Surg 2021;74(3):670–1. DOI: 10.1016/j.bjps.2020.10.087</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Ruiz E.S., Karia P.S., Besaw R., Schmults C.D. Performance of the American Joint Committee on Cancer Staging Manual, 8th edition vs. the Brigham and Women’s Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma. JAMA Dermatol 2019;155:819–25. DOI: 10.1001/jamadermatol.2019.0032</mixed-citation><mixed-citation xml:lang="ru">Ruiz E.S., Karia P.S., Besaw R., Schmults C.D. Performance of the American Joint Committee on Cancer Staging Manual, 8th edition vs. the Brigham and Women’s Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma. JAMA Dermatol 2019;155:819–25. DOI: 10.1001/jamadermatol.2019.0032</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23. Pavia G., Gargiulo L., Valenti M. et al. Skin cancers: How to balance the risks and benefits of surgery during COVID-19 pandemic (a Northern Italy single-center experience). Int J Dermatol 2020;59(10):1287–9. DOI: 10.1111/ijd.15086</mixed-citation><mixed-citation xml:lang="ru">Pavia G., Gargiulo L., Valenti M. et al. Skin cancers: How to balance the risks and benefits of surgery during COVID-19 pandemic (a Northern Italy single-center experience). Int J Dermatol 2020;59(10):1287–9. DOI: 10.1111/ijd.15086</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">24. NCCN. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Advisory Statement for Non-Melanoma Skin Cancer Care during the COVID-19 Pandemic. 2020. Available at: https://www.nccn.org/covid-19/pdf/NCCN-NMSC.pdf.</mixed-citation><mixed-citation xml:lang="ru">NCCN. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Advisory Statement for Non-Melanoma Skin Cancer Care during the COVID-19 Pandemic. 2020. Available at: https://www.nccn.org/covid-19/pdf/NCCN-NMSC.pdf.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">25. Surgery AcoM. American College of Mohs Surgery: COVID-19 (Coronavirus) Preparedness. 2020. Available at: https://www.mohscollege.org/UserFiles/AM20/Member%20Alert/COVIDAlert3March20.pdf.</mixed-citation><mixed-citation xml:lang="ru">Surgery AcoM. American College of Mohs Surgery: COVID-19 (Coronavirus) Preparedness. 2020. Available at: https://www.mohscollege.org/UserFiles/AM20/Member%20Alert/COVIDAlert3March20.pdf.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">26. Shannon A.B., Sharon C.E., Straker R.J. 3rd et al. The impact of the COVID-19 pandemic on the presentation status of newly diagnosed melanoma: a single institution experience. J Am Acad Dermatol 2021;84(4):1096–8. DOI: 10.1016/j.jaad.2020.12.034</mixed-citation><mixed-citation xml:lang="ru">Shannon A.B., Sharon C.E., Straker R.J. 3rd et al. The impact of the COVID-19 pandemic on the presentation status of newly diagnosed melanoma: a single institution experience. J Am Acad Dermatol 2021;84(4):1096–8. DOI: 10.1016/j.jaad.2020.12.034</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">27. Capitelli-McMahon H., Hurley A., Pinder R. et al. Characterising non-melanoma skin cancer undergoing surgical management during the COVID-19 pandemic. J Plast Reconstr Aesthet Surg 2021;74(3):668–70. DOI: 10.1016/j.bjps.2020.10.042</mixed-citation><mixed-citation xml:lang="ru">Capitelli-McMahon H., Hurley A., Pinder R. et al. Characterising non-melanoma skin cancer undergoing surgical management during the COVID-19 pandemic. J Plast Reconstr Aesthet Surg 2021;74(3):668–70. DOI: 10.1016/j.bjps.2020.10.042</mixed-citation></citation-alternatives></ref></ref-list></back></article>
